Home › Funds › RAFFLES ASSOCIATES LP › LCTX

RAFFLES ASSOCIATES LP position in LCTX

LINEAGE CELL THERAPEUTICS IN · Health Care

RAFFLES ASSOCIATES LP reported holding 5,197,788 shares of LCTX (LINEAGE CELL THERAPEUTICS IN) in its Q2 2026 13F filing — a position valued at US$6.8M, representing 5.80% of its reported portfolio and ranking #5 among its reported holdings. RAFFLES ASSOCIATES LP has disclosed LCTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)5.20M sh
Reported value held$6.81M
Portfolio Weight5.80%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How RAFFLES ASSOCIATES LP's LCTX position evolved

RAFFLES ASSOCIATES LP first disclosed a stake in LCTX in Q3 2023 at 1,587,739 shares (US$1.9M). The position peaked in Q3 2025 at 5,387,788 shares, worth US$9.1M. Across 12 filings, RAFFLES ASSOCIATES LP increased the stake 6 time(s), trimmed it 2 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 5,197,788 shares valued at US$6.8M — a reduction of -165,000 shares quarter over quarter.. Notable position changes include a 34% increase in Q4 2023 (shares rose 36% over the following quarter), a 51% increase in Q1 2024 (shares fell 32% over the following quarter), a 36% increase in Q2 2024 (shares fell 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.59M $1.87M New
Q4 2023 2.13M $2.32M Add
Q1 2024 3.21M $4.75M Add
Q2 2024 4.36M $4.35M Add
Q3 2024 4.51M $4.08M Add
Q4 2024 5.49M $2.76M Add
Q1 2025 5.64M $2.55M Add
Q2 2025 5.39M $4.89M Reduce
Q3 2025 5.39M $9.11M Hold
Q4 2025 5.36M $8.96M Hold
Q1 2026 5.36M $8.47M Hold
Q2 2026 5.20M $6.81M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LCTX and 13F data

LCTX (LINEAGE CELL THERAPEUTICS IN) is a Health Care company. 36 other funds we track also report a position in LCTX — the largest reported positions include BROADWOOD CAPITAL INC (US$64.9M), Defender Capital, LLC. (US$6.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LCTX

All LCTX fund holders →

FAQ

How long has RAFFLES ASSOCIATES LP held LCTX?

RAFFLES ASSOCIATES LP has disclosed LCTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is RAFFLES ASSOCIATES LP's current position in LCTX?

As of Q2 2026, RAFFLES ASSOCIATES LP holds 5.20M shares of LCTX (LINEAGE CELL THERAPEUTICS IN), valued at $6.81M, representing 5.80% of its reported portfolio and ranking #5.

Has RAFFLES ASSOCIATES LP been buying or selling LCTX?

In the latest 13F filing (Q2 2026), RAFFLES ASSOCIATES LP reduced its position in LCTX. The position peaked in Q3 2025 at 5.39M shares.

Which other funds hold LCTX?

Other major institutional holders of LCTX include BROADWOOD CAPITAL INC, Defender Capital, LLC., among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.